PURPOSE: Recent studies describe inferior outcomes in newly diagnosed multiple myeloma (NDMM) patients with t(11
14) treated with novel agents. MATERIALS AND METHODS: We analyzed 240 NDMM transplant eligible (TE) patients who received triplet induction regimen in the GEM05MENOS65 (bortezomib, thalidomide and dexamethasone - VTD) and GEM2012 (bortezomib, lenalidomide and dexamethasone - VRD) clinical trials. RESULTS: t(11
14) and standard risk (SR) non-t(11
14) were prevalent in 51 (21%) and 189 (79%) patients, respectively. Patients with t(11
14) treated with VTD had a lower overall response rate (ORR) (84% vs. 97%, P = .044) and lower negative minimal residual disease (MRD) (7.7% vs 35.1%, P = .049) after induction, as compared to SR non-t(11
14), while there were no differences in ORR (87% vs. 89%) or negative MRD (13.2% vs. 24.4%, P = .2) for these 2 subgroups in patients treated with VRD. The presence of t(11
14) impacted negatively on PFS in patients with VTD (hazard ratio 2.70
P = .005), while no differences were observed in those treated with VRD. CONCLUSION: TE NDMM patients harboring t(11
14) had an inferior outcome compared with SR patients when receiving induction therapy with VTD while no differences were observed when receiving a lenalidomide containing regimen.